Log In
BCIQ
Print this Print this
 

SGN-CD123A

  Manage Alerts
Collapse Summary General Information
Company Seattle Genetics Inc.
DescriptionAntibody-drug conjugate (ADC) composed of an anti-IL-3 receptor alpha (CD123) mAb and a pyrrolobenzodiazepine (PBD) dimer
Molecular Target Interleukin-3 (IL-3) receptor alpha (CD123)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML); Treat relapsed or refractory acute myelogenous leukemia (AML)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today